Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease
- PMID: 23086579
- PMCID: PMC3549239
- DOI: 10.1007/s11239-012-0821-8
Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease
Abstract
Altered fibrin clot structure has been reported both in patients with coronary artery disease (CAD) and those with type 2 diabetes mellitus (DM2). The aim of the present study was to evaluate plasma fibrin clot permeability and susceptibility to lysis in patients with DM2 and CAD. We studied 132 consecutive CAD patients, including 67 subjects with DM2, scheduled for elective coronary artery bypass grafting surgery. Ex vivo plasma fibrin clot permeability (K(s)) and lysis time (t(50%)) induced by 1 μg/mL recombinant tissue plasminogen activator (tPA), along with plasma levels of plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), tPA, von Willebrand factor (vWF), P-selectin, soluble CD40 ligand (sCD40L), were measured. Diabetic and non-diabetic patients did not differ in regard to demographics and remaining cardiovascular risk factors. Concomitant DM2 was associated with higher glucose (+24.3%, p < 0.001), fibrinogen (+9.0%, p = 0.037), PAI-1 (+58.7%, p < 0.001), tPA (+24.0%, p < 0.001) and P-selectin (+12.2%, p < 0.001). Compared with the non-diabetic group, the CAD patients with DM2 had lower K(s) (-6.1%, p = 0.02) and prolonged t(50%) (+5.1%, p = 0.04). Multiple regression analysis of the whole study group showed that vWF, PAI-1, fibrinogen and DM2 were the independent predictors of t(50%) (R(2) = 0.58, p < 0.001), while only vWF was an independent predictor of K(s) (R(2) = 0.22, p < 0.001). This study indicates that DM2 is potent enough to unfavorably affect plasma fibrin clot characteristics despite abnormal clot phenotype typically observed in CAD. Of note, platelet and endothelial markers appear to contribute to fibrin clot properties in CAD concomitant with DM2.
Figures



Similar articles
-
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.Thromb Haemost. 2014 Dec;112(6):1142-50. doi: 10.1160/TH14-05-0468. Epub 2014 Sep 4. Thromb Haemost. 2014. PMID: 25187394
-
Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.Thromb Haemost. 2014 Apr 1;111(4):685-93. doi: 10.1160/TH13-07-0566. Epub 2013 Dec 5. Thromb Haemost. 2014. PMID: 24306139
-
Altered plasma fibrin clot properties in essential thrombocythemia.Platelets. 2016;27(2):110-6. doi: 10.3109/09537104.2015.1042967. Epub 2015 May 19. Platelets. 2016. PMID: 25989112
-
Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis.Semin Thromb Hemost. 2021 Feb;47(1):11-17. doi: 10.1055/s-0040-1714398. Epub 2020 Oct 5. Semin Thromb Hemost. 2021. PMID: 33017849 Review.
-
Fibrin clot properties in coronary artery disease: new determinants and prognostic markers.Pol Arch Intern Med. 2021 Nov 30;131(11):16113. doi: 10.20452/pamw.16113. Epub 2021 Oct 8. Pol Arch Intern Med. 2021. PMID: 34623063 Review.
Cited by
-
Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.Cardiovasc Diabetol. 2015 Mar 8;14:30. doi: 10.1186/s12933-015-0192-5. Cardiovasc Diabetol. 2015. PMID: 25848817 Free PMC article.
-
Acute-phase proteins and oxidative stress in patients undergoing coronary artery bypass graft: comparison of cardioplegia strategy.Kardiochir Torakochirurgia Pol. 2017 Mar;14(1):16-21. doi: 10.5114/kitp.2017.66924. Epub 2017 Mar 31. Kardiochir Torakochirurgia Pol. 2017. PMID: 28515743 Free PMC article.
-
Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.Cardiovasc Diabetol. 2018 Nov 22;17(1):146. doi: 10.1186/s12933-018-0789-6. Cardiovasc Diabetol. 2018. PMID: 30466424 Free PMC article.
-
Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.Cardiovasc Diabetol. 2021 Feb 18;20(1):47. doi: 10.1186/s12933-021-01230-9. Cardiovasc Diabetol. 2021. PMID: 33602240 Free PMC article.
-
Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.Sci Rep. 2017 Aug 29;7(1):9680. doi: 10.1038/s41598-017-09860-4. Sci Rep. 2017. PMID: 28851981 Free PMC article.
References
-
- Polakowska M, Piotrowski W. Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study—WOBASZ. Pol Arch Med Wewn. 2011;121:156–163. - PubMed
-
- Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J. 2007;28:88–136. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous